NASDAQ
15.05.25 | 16:40
1,445 US-Dollar
+4,71 % +0,065
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INOZYME PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | Inozyme Pharma GAAP EPS of -$0.44 misses by $0.04 | 4 | Seeking Alpha | ||
| Mi | Inozyme Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mi | Inozyme Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.04. | H.C. Wainwright maintains Buy on Inozyme stock with $16 target | 6 | Investing.com | ||
| 10.04. | Inozyme Pharma Inc.: Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency | 3 | GlobeNewswire (USA) | ||
| 11.03. | H.C. Wainwright maintains Buy on Inozyme stock with $16 target | 16 | Investing.com | ||
| 10.03. | Inozyme Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Inozyme Pharma GAAP EPS of -$1.62 | 2 | Seeking Alpha | ||
| 10.03. | Inozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights | 242 | GlobeNewswire (Europe) | - Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction... ► Artikel lesen | |
| 10.03. | Inozyme Pharma, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.03. | Inozyme Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 21.02. | Inozyme Pharma Inc.: Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 | 8 | GlobeNewswire (USA) | ||
| 10.01. | Inozyme meldet vielversprechende Daten zu Behandlungen seltener Krankheiten | 26 | Investing.com Deutsch | ||
| 10.01. | Inozyme reports promising data on rare disease treatments | 4 | Investing.com | ||
| 10.01. | Inozyme Pharma, Inc. - 8-K, Current Report | 14 | SEC Filings | ||
| 05.11.24 | Inozyme Pharma Inc.: Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights | 207 | GlobeNewswire (Europe) | - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 - - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric... ► Artikel lesen | |
| 24.10.24 | Inozyme Pharma Inc.: Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 | 208 | GlobeNewswire (Europe) | - INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with... ► Artikel lesen | |
| 17.10.24 | Inozyme Pharma Inc.: Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 | 171 | GlobeNewswire (Europe) | BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases... ► Artikel lesen | |
| 25.07.24 | Inozyme Pharma Inc.: Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function | 229 | GlobeNewswire (Europe) | - Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25... ► Artikel lesen | |
| 02.07.24 | Inozyme Pharma Inc.: Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency | 166 | GlobeNewswire (Europe) | BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,85 | -0,67 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| BB BIOTECH | 30,300 | +0,50 % | BB Biotech: Vier Verkäufe und ein neuer Titel im Portfolio | Die Aktie der Schweizer Biotech-Beteiligungsgesellschaft hat in den vergangenen Monaten deutlich unter der Schwäche im Sektor gelitten. Insbesondere Small- und Mid-Cap-Unternehmen standen unter Druck... ► Artikel lesen | |
| QIAGEN | 37,390 | -0,24 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| NOVAVAX | 5,460 | +2,40 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| STRYKER | 348,70 | +0,81 % | Aktienmarkt: Stryker-Aktie tritt auf der Stelle (346,1390 €) | Wenig Kursbewegung zur Stunde bei der Aktie von Stryker . Die Aktie notiert aktuell bei 386,71 US-Dollar. Kaum verändert im Vergleich zu der letzten Notierung des vorigen Handelstages zeigt sich derzeit... ► Artikel lesen | |
| ILLUMINA | 71,78 | +2,48 % | Illumina, Inc.: Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 | Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)
GAAP operating margin of 15.8% and non-GAAP operating... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 31,600 | -1,25 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| AAP IMPLANTATE | 1,200 | +1,69 % | EQS-News: aap Implantate AG: aap startet stabil ins Geschäftsjahr 2025 - Wachstum in der umsatzstärksten Region EMEA | EQS-News: aap Implantate AG
/ Schlagwort(e): Quartals-/Zwischenmitteilung
aap startet stabil ins Geschäftsjahr 2025 - Wachstum in der umsatzstärksten Region EMEA
06.05.2025... ► Artikel lesen | |
| OCUGEN | 0,576 | -7,75 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,380 | -3,11 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,700 | -0,34 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,950 | -1,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,277 | +3,69 % | Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting | Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,562 | -5,39 % | Evotecs KI-Goldgrube, Defence Therapeutics Milliarden-Märkte, Novo Nordisks Diät-Revolution: So verdienen Anleger mit | Die Gesundheitsbranche befindet sich im Umbruch. Algorithmen beschleunigen die Arzneimittelforschung um Jahre, Milliarden fließen in personalisierte Therapien, und Börsen feiern Biotech-Aktien. Doch... ► Artikel lesen |
INOZYME PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,065 (+4,71 %) liegt der Kurs bei 1,445 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INOZYME PHARMA INC finden Sie auf Wallstreet Online.